Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)
Type 2 Diabetes Mellitus

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- is in good health
- is a nonsmoker
- is willing to follow all study guidelines
Exclusion Criteria:
- has or has a history of any illness or condition that might confound the results of the study or make participation unsafe for the participant
- is a nursing mother
- is unwilling to consume the required high-fat breakfast
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Sita + Met then Sita/Met FDC
Sita/Met FDC then Sita + Met
Participants receive sitagliptin (Sita) 50 mg and metformin (Met) 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg FDC tablet administered as a single dose during Period 2.
Participants receive sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2.